Skip to Main Content

Paper Details

Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia.
Pediatr Blood Cancer
55
2018
-ZNF384, -ZNF384 fusion, AML, AML relapse cell population, B-ALL, B-lymphoblastic leukemia, CAR, CAR-T, KMT2A (, KMT2A (mixed lineage leukemia) rearrangements, T, T-cell, TCF3, TCF3-, ZNF384, ZNF384-rearrangements, acute leukemias, acute myeloid leukemia, chimeric antigen receptor, hematopoietic stem cell, mixed lineage leukemia, patient, patients, pro-B-cell
Author NameAffiliation
Matthew J OberleyChildren's Hospital Los Angeles, Keck School of Medicine, University of Southern California
Jianling JiChildren's Hospital Los Angeles, Keck School of Medicine, University of Southern California
Alan S WayneChildren's Center for Cancer and Blood Diseases and Division of Hematology, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
Alan S WayneChildren's Center for Cancer and Blood Diseases and Division of Hematology, Children's Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
Gordana RacaChildren's Hospital Los Angeles, Keck School of Medicine, University of Southern California
  • 1 - 5

Datasets

Release 1.2